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We report the long-term morbidity and mortality of 105 pediatric patients who developed chronic graft-
versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). According to
the consensus criteria of the National Institutes of Health, the global severity of cGVHD was mild in 26 pa-
tients (25%), moderate in 30 patients (29%), and severe in 49 patients (47%). Patients with severe cGVHD had a
signiﬁcantly lower cumulative incidence of cGVHD remission and higher probability of continuing cGVHD at
8 years from cGVHD diagnosis compared with those with mild or moderate cGVHD. The 10-year cumulative
incidence of nonrelapse mortality in severe cGVHD patients was signiﬁcantly higher and the probability of
disease-free survival was signiﬁcantly lower than those among patients with mild and moderate cGVHD. Of
the 59 patients who survived for more than 5 years, 20 (34%) (4 with moderate and 16 with severe cGVHD)
had persistent functional impairment caused by cGVHD with a Karnofsky/Lansky performance score of 90% in
3 patients, 80% in 4 patients, and below 70% in 13 patients at the time of relapse, death, or last follow-up.
Better therapeutic strategies are needed to lower the incidence of severe cGVHD, considering the longer
life expectancy of pediatric HSCT survivors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION to persist for at least 15 years after HSCT [3]. The major cause
Chronic graft-versus-host disease (cGVHD) is the major
cause of nonrelapse mortality (NRM) in patients who survive
for more than 2 years after allogeneic hematopoietic stem
cell transplantation (HSCT) [1,2]. A signiﬁcantly increased
risk of NRM among patients with cGVHD has been reporteddgments on page 1979.
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ty for Blood and Marrow Transplantation.of death is life-threatening infection resulting from long-
lasting immunosuppressive treatment (IST), followed by
progressive organ failure due to cGVHD involvement [1,4,5].
In addition, cGVHD can lead to substantial deﬁcits in quality
of life (QOL), such as respiratory distress, joint contractures,
loss of sight, and sexual inactivity [4-6]. Prolonged treatment
with steroids, which are mainly used in the ﬁrst-line treat-
ment of cGVHD, may further compromise QOL. Several
studies demonstrated that cGVHD has a signiﬁcant associa-
tion with the adverse health status of HSCT survivors [3,5,6].
For pediatric HSCT recipients, considering their long life
expectancy and developmental process, the decreased
Table 1
Patient Characteristics
Characteristic Value
Age, median (range), yr 9 (0-18)
Sex
Male 57 (54)
Female 48 (46)
Diagnosis
ALL 50 (48)
AML 19 (18)
CML 8 (8)
MDS/JMML 14 (13)
NHL 5 (5)
AA 6 (6)
WAS 3 (3)
Disease risk
Low 62 (59)
High 43 (41)
Donor
HLA-matched related 31 (30)
HLA-mismatched related 11 (10)
HLA-matched unrelated 51 (49)
HLA-mismatched unrelated 12 (11)
Stem cell source
BM 87 (83)
CB 10 (10)
PB 8 (8)
Conditioning regimen
Myeloablative 94 (90)
Reduced-intensity 11 (10)
GVHD prophylaxis
MTX 6 (6)
CsA  sMTX 31 (30)
Tac  sMTX 68 (65)
Prior acute GVHD grade
0 16 (15)
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concern because these debilitating sequelae are, in many
cases, persistent or irreversible. A number of studies have
evaluated the risk factors for the development of cGVHD
after HSCT in adult and children [7-12] or for survival and
NRM for adult patients who developed cGVHD [13-17].
However, only a few studies have reported the long-term
consequences of cGVHD in children, including the probabil-
ity of resolution of cGVHD or the probability of discontinu-
ation of IST [10,14], and little is known about the prevalence
of long-lasting symptoms of cGVHD and the physical status
in pediatric HSCT survivors.
The present study aimed to investigate the long-term
morbidity and mortality of children with cGVHD, focusing
on the prevalence of functional impairment in the involved
organs and performance status, affecting their QOL and
mortality.
Another aim of the present study was to assess the
prognostic implication of the consensus criteria of the Na-
tional Institutes of Health (NIH) [5] for children with cGVHD.
Since the NIH criteriawere initially proposed in 2005, several
studies have evaluated the utility of the criteria for predicting
the prognosis of patients with cGVHD, mostly adult HSCT
recipients [15,18-20]. To date, little is known about the
applicability of the NIH criteria in pediatric HSCT recipients
[21]. Therefore, we retrospectively reclassiﬁed the severity of
cGVHD according to the NIH criteria for pediatric patients
with cGVHD included in the present study and analyzed the
long-term outcomes, including relapse, NRM, survival, and
outcome of cGVHD.I 13 (12)
II 41 (39)
III-IV 35 (33)
Follow-up period of survivors from diagnosis of chronic
GVHD, median (range), mo
96 (12-228)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; JMML,
juvenile myelomonocytic leukemia; NHL, non-Hodgkin lymphoma; AA,
aplastic anemia; WAS, Wiscott-Aldrich syndrome; CB, cord blood; MTX,
methotrexate; CsA, cyclosporine A; sMTX, short-term methotrexate; Tac,
tacrolimus.PATIENTS AND METHODS
Patients and Transplantation Procedures
Data of patients who developed cGVHD after allogeneic HSCTconducted
at the Department of Pediatrics, National Kyushu Cancer Center between
1995 and 2012 were retrospectively analyzed. All patients or their guardians
provided written informed consent to all aspects of the HSCT procedure.
This study was approved by the institutional review board of the National
Kyushu Cancer Center and was conducted in accordance with the Declara-
tion of Helsinki. All patients achieved neutrophil engraftment and survived
for at least 100 days. We reviewed the department’s HSCT database, in
which patients’ data for procedures and outcomes of HSCT were recorded
using a uniform data sheet. Follow-up data regarding the status of under-
lying disease and physical health status, including cGVHD, transplantation-
related complications, late effects, and performance scores, were updated at
least annually or as appropriate according to patients’ visits to our clinic. The
information related to cGVHD includes onset day, affected organs, type of
onset (de novo, quiescent, or progressive), stage (limited or extensive), and
treatments. We also reviewed the medical records of each patient to obtain
data regarding the clinical course and outcome of cGVHD, including
response to treatments, functional status of involved organs, duration of IST,
and adverse events. Data of the patients who had not visited our clinic for
more than 1 year were obtained using a questionnaire created for use in the
present study from referring hospitals that provided primary care for
patients.
A total of 105 patients were reclassiﬁed as cases of classic cGVHD or
overlap syndrome, as outlined in the NIH criteria. Patient characteristics are
summarized in Table 1. The patients consisted of 57 boys and 48 girls with a
median age of 9 (range, 0 to 18) years at the time of HSCT. Themost common
diagnosis was acute lymphoblastic leukemia (48%), followed by acute
myeloid leukemia (18%). Nine patients (9%) had nonmalignant disease.
Sixty-two patients (59%) were assigned to the low-risk group for disease
recurrence, including acute leukemia in ﬁrst or second remission, chronic
myeloid leukemia in ﬁrst chronic phase, myelodysplastic syndromewithout
excess blasts, non-Hodgkin lymphoma in ﬁrst or second remission, and
nonmalignant diseases. The high-risk group included all other diseases and
stages. A myeloablative conditioning regimen was used in 94 patients (90%)
and the remaining 11 (10%) received a reduced-intensity conditioning
regimen. Bone marrow (BM) was the most common stem cell source (83%)
followed by cord blood (10%) and peripheral blood (PB) stem cells (8%).
Thirty-one patients (30%) underwent HSCT from HLA-matched related do-
nors, 51 (49%) from matched unrelated donors, and 23 (21%) frommismatched donors. Seventy-six patients (73%) had prior grades II to IV
acute GVHD (aGVHD) and 5 patients received donor lymphocyte infusions
before developing cGVHD.Deﬁnitions and Statistical Analysis
The severity of cGVHD was reclassiﬁed according to the NIH criteria [5].
In these criteria, each organ site involved is scored according to a 4-point
scale (0 to 3), in which with a score of 0 indicates no symptoms, a score
of 1 indicates no clinically signiﬁcant functional impairment, a score of 2
indicates clinically signiﬁcant but not severe impairment, and a score of 3
indicates severe impairment. The overall clinical severity of cGVHD was
also evaluated using the global scoring classiﬁed in the criteria as mild,
moderate, or severe according to the number of organs affected and the
severity in each affected organ. Mild cGVHD involved 1 or 2 organs, with a
maximum score of 1. Moderate cGVHD involved at least 1 organ with a
maximum score of 2, or 3 or more organs with a maximum score of 1.
Severe cGVHD indicated major disability with a score of 3 in any organ. A
lung score of 1 was considered moderate and a score of 2 or greater was
considered severe cGVHD. In the present study, cGVHD remission was
deﬁned as the achievement of score 0 or 1 (no clinically signiﬁcant func-
tional impairment) in all affected organs without systemic IST. To the
contrary, continuing cGVHD was deﬁned as at least 1 sustained symptom
with clinically signiﬁcant impairment (score of 2 or 3, or score of 1 to 3 in
the lungs), including both active disease and past tissue damage, or
continuation of systemic IST.
Disease recurrencewas deﬁned as any evidence of malignancy regardless
of morphological, cytogenetic, or molecular relapse after achievement of
Table 2
Characteristics of cGVHD
Characteristic Value
Global score (NIH)
Mild 26 (25)
Moderate 30 (29)
Severe 49 (47)
Involved organ
Skin 84 (29)
Mouth 69 (24)
Liver 44 (15)
GI tract 25 (9)
Eyes 22 (8)
Lungs 14 (5)
Joint and fascia 7 (2)
Others 20 (7)
Number of involved organs
1 or 2 50 (48)
3 55 (52)
IST just before onset of chronic GVHD
None 26 (25)
CNI 41 (39)
CNI þ steroid  MTX/MMF 27 (26)
Steroid  MTX 10 (10)
MTX 1 (1)
Initial IST for chronic GVHD*
None 29 (28)
CNI 10 (10)
CNI þ steroid 4 (4)
Steroid 46 (44)
Steroid þ MTX 2 (2)
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ient chimerism after the achievement of complete donor chimerism for
nonmalignant diseases. NRM was deﬁned as death from any cause without
evidence of disease recurrence. Disease-free survival (DFS) was deﬁned as
the time from the day of cGVHD diagnosis to the day of the last follow-up or
ﬁrst event, including disease recurrence and NRM. The probability of DFS
was estimated by the Kaplan-Meier method. Univariate analysis of DFS was
performed using the log-rank test. The cumulative incidence of disease
recurrence and NRM were estimated on the basis of the cumulative inci-
dence method treating each recurrent disease and NRM as a competing risk
for the other. The groups were compared using Gray’s test. Variables
considered were patient’s age, sex, disease risk group, donor type, stem cell
source, HLA disparity, conditioning regimen, use of total body irradiation
(TBI)  10 Gy in conditioning regimen, time of cGVHD onset, presence of IST
just before cGVHD, number of involved organs, number of treatment agents
for cGVHD, global score by NIH criteria, presence of lung involvement, liver
involvement, thrombocytopenia, previous II to IV acute GVHD, and cyto-
megalovirus (CMV) antigenemia. The factors that were found to be signiﬁ-
cant at a P value of less than .05 were entered into the multivariate analysis.
Multivariate analysis was performed using the Cox proportional hazard
regression model for DFS and the method of Fine and Gray for disease
recurrence and NRM. The cumulative incidence of cGVHD remission was
calculated, with disease recurrence and NRM considered as a competing
risk. The cumulative incidence of disease recurrence as well as NRM and
cGVHD remissionwere deﬁned as the time from the day of cGVHD diagnosis
to the day of each event. The probability of continuing cGVHDwas estimated
using the Kaplan-Meier method calculating as the time from the day of
cGVHD diagnosis to the day of the last follow-up or the ﬁrst event, including
disease recurrence, NRM, and cGVHD remission. Statistical analyses were
performed using EZR software (Saitama Medical Center, Jichi Medical Uni-
versity) and a P value of less than .05 was considered to be statistically
signiﬁcant.MTX 13 (12)
MMF 1 (1)
Number of agents used for IST of cGVHD
0-1 37 (35)
2-3 49 (47)
4 19 (18)
Time from HSCT to onset of chronic GVHD,
median (range), d
133 (58-617)
MMF indicates mycophenolate mofetil.
Data presented are n (%), unless otherwise indicated.
* An increase in the dose of CNI or steroid in patients who were already
being treated with these agents was considered initial IST.RESULTS
cGVHD
The clinical features of cGVHD are summarized in Table 2.
The median time from HSCT to the onset of cGVHD was
133 days (range, 58 to 617). The global severity of cGVHDwas
mild in 26 patients (25%), moderate in 30 patients (29%), and
severe in 49 patients (47%), according to NIH criteria. His-
tological diagnosis of cGVHD was determined in 26 patients
using specimens of skin in 5 patients, liver in 6, oral mucosa
in 4, gastrointestinal (GI) in 9, and lung in 2. The most
frequently affected organs were the skin (29%) and mouth
(24%), followed by liver (15%), GI tract (9%), and eyes (8%).
Other manifestations included thrombocytopenia (5%),
eosinophilia (1%), and serositis (1%). Fifty-ﬁve patients (52%)
had involvement of 3 or more organs. Sixty-three patients
(60%) had received calcineurin inhibitor (CNI) with or
without a steroid immediately before the onset of chronic
GVHD, whereas 26 patients (25%) had not received any IST.
After onset of cGVHD, 29 patients did not receive any new or
additional systemic IST because of mild or moderate cGVHD
requiring only local therapy in 25 patients, parents’ refusal of
systemic IST in 2, and unknown reasons in 2. On the other
hand, initial systemic ISTwas administered to 76 patients. An
increase in the dose of steroids or CNI was also considered as
initial systemic IST if patients were already being treated
with these agents. Fifty-two patients (68%) received steroids
(prednisone or methylprednisolone) with or without other
agents, and 24 patients (32%) received a CNI, weekly low-
dose methotrexate, or mycophenolate mofetil as initial IST.
The reasons for not using steroids as initial IST in these 24
patients were as follows: long-lasting administration of
steroids until the onset of cGVHD in 13 patients, develop-
ment of cGVHD during tapering of the dose of CNI in 5,
parents’ refusal of steroid administration in 2, and unknown
in 4. In 19 patients (18%), 4 ormore agentswere used through
the treatment of cGVHD.Disease Recurrence
A total of 18 patients (17%), all of who had malignant
disease, experienced disease recurrence at a median dura-
tion of 298 days (range, 66 to 2995 days) after the diagnosis
of cGVHD. Eight (44%) patients had mild cGVHD by NIH
global score, 6 (33%) had moderate disease, and 4 (22%) had
severe cGVHD. The estimated cumulative incidence of
relapse at 5 years for the entire cohort was 16.3% (95% con-
ﬁdence interval [CI], 10.0 to 24.1) and the incidence in pa-
tients with severe cGVHD (8.3%; 95% CI, 2.6 to 18.3) was
signiﬁcantly lower compared with those with mild and
moderate cGVHD (23.4%; 95% CI, 13.2 to 35.2) (P ¼ .027)
(Figure 1A). In multivariate analysis, TBI  10 Gyecontaining
conditioning regimen and mild cGVHD were associated with
higher cumulative incidence of relapse, whereas positive
CMV antigenemia after HSCT and severe cGVHD were factors
associated with a lower incidence of relapse (Table 3).NRM
Overall, 22 patients (21%) died of nonrelapse causes at a
median of 382 days (range, 26 to 5975 days) after the onset of
cGVHD. Eighteen (82%) patients had severe cGVHD, 3 (14%)
had moderate, and 1 (5%) had mild cGVHD. The causes of
death among these patients are shown in Table 4. The major
causes of death were fatal infections associated with IST,
followed by bronchiolitis obliterans (BO). The estimated
Figure 1. Outcomes of patients with cGVHD according to the NIH global severity. (A) Cumulative incidence of disease recurrence. (B) Cumulative incidence of NRM.
(C) Probability of DFS. (D) Cumulative incidence of cGVHD remission.
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and 15 years were 15.8% (95% CI, 9.4 to 23.7), 18.1% (95% CI,
11.2 to 26.4), and 24.4% (95% CI, 15.3 to 34.6), respectively.
The cumulative incidence of NRM at 10 years was signiﬁ-
cantly higher in patients with severe cGVHD (34.5%, 95% CI,
21.0 to 48.5) compared with that in those with mild cGVHD
(3.8%; 95% CI, .3 to 16.9) or moderate cGVHD (4.4%; 95% CI, .3
to 19.1) (P ¼ .0012) (Figure 1B). NRM of patients with mod-
erate and severe cGVHD continued to increase even after
10 years of the onset of cGVHD. In multivariate analysis,
factors associated with higher NRM were severe cGVHD,
cGVHD in the lungs, 3 or more organs affected by cGVHD, PB
as the stem cell source, and positive CMV antigenemia after
HSCT (Table 3).
DFS
Themedian follow-up of survivors was 96months (range,
12 to 228 months) after diagnosis of cGVHD. In the entire
cohort, the probabilities of DFS at 5, 10, and 15 years were
69.2% (95% CI, 59.0 to 77.3), 66.6% (95% CI, 56.2 to 75.1), and
58.5% (95% CI, 45.6 to 69.3), respectively. Ten-year DFS of
patients with mild, moderate, and severe cGVHD was 71.2%
(95% CI, 48.6 to 85.2), 78.8% (95% CI, 58.6 to 89.9) and 57.3%
(95% CI, 41.8 to 70.2), respectively (Figure 1C). The survival
curve of patients with mild cGVHD reached a plateau at
5 years after the diagnosis of cGVHD, whereas that of pa-
tients with moderate and severe cGVHD continued to
decrease and the 17-year DFS was 64.7% (95% CI, 38.7 to 81.9)
and 34.7% (95% CI, 9.2 to 62.6), respectively. The DFS of pa-
tients with severe cGVHD was signiﬁcantly lower compared
with those with mild and moderate cGVHD (P ¼ .037). In
multivariate analysis, TBI >10 Gyecontaining conditioning
regimen and cGVHD in the liver and lungs were each asso-
ciated with lower DFS (Table 3).Outcomes of Chronic GVHD
Except for the patients who relapsed or died, 44 patients
achieved cGVHD remission at amedian of 415 days (range, 30
to 2337 days) from diagnosis of cGVHD. Of the 44 patients, 17
(39%) patients had mild cGVHD, 18 (41%) had moderate dis-
ease, and only 9 (20%) had severe cGVHD. In the entire
cohort, the cumulative incidence of cGVHD remission at
8 years was 44.6% (95% CI, 34.4 to 54.3). The cumulative
incidence of remission at 8 years in patients with severe
cGVHD was signiﬁcantly lower (21.1%; 95% CI, 10.1 to 34.8)
than that of patients with mild cGVHD (65.4%; 95% CI, 41.8 to
81.3) or moderate cGVHD (64.6%; 95% CI, 42.9 to 79.8)
(P < .001) (Figure 1D). On the other hand, the probability of
continuing cGVHD at 8 years was 20.9% (95% CI, 13.3 to 29.7)
in the entire cohort; 3.8% (95% CI, .3 to 16.4) in patients with
mild cGVHD, 11.4% (95% CI, 2.9 to 26.3) in patients with
moderate disease, and 36.1% (95% CI, 21.9 to 50.4) in patients
with severe cGVHD (P < .001) (Figure 2).
Prognosis and Status of cGVHD for Long-term Survivors
At the time of the present study, 59 patients survived for
more than 5 years from diagnosis of cGVHD. Among them,
relapse occurred in 1 patient (2%) and NRM occurred in 7
patients (12%). The causes of NRM were BO (n ¼ 3), bacterial
pneumonia (n ¼ 1), second malignant neoplasm (n ¼ 1),
suicide (n ¼ 1), and accident (n ¼ 1). At the time of relapse,
death, or last follow-up, 39 patients (66%) were in remission
of cGVHD, with a Karnofsky/Lansky performance score of
100% in 28 patients, 90% in 9 patients, and 0% in 2 deceased
patients. On the other hand, 20 patients (34%), including 4
with moderate cGVHD and 16 with severe cGVHD, had
continuing cGVHD with a Karnofsky/Lansky performance
score of 90% in 3 patients, 80% in 4 patients, and below 70%
in 13 patients; the organs with persistent functional
Table 3
Multivariate Analysis of Risk Factors for Disease Recurrence, NRM, and DFS
in Children with cGVHD
Risk Factor HR 95% CI P
Disease recurrence
TBI  10 Gy
No 1 .01
Yes 4.86 1.4-16.5
CMV antigenemia
Negative 1 .01
Positive .2 .05-.7
NIH grade
Mild and moderate 1 .001
Severe .07 .01-.4
NRM
Stem cell source
BM and CB 1 .01
PB 1.99 1.2-3.4
CMV antigenemia
Negative 1 .04
Positive 2.8 1.0-7.6
NIH grade
Mild and moderate 1 .02
Severe 3.07 1.2-7.8
No. of involved organ
1 or 2 1 .02
3 3.98 1.2-13.0
Lung involvement
No 1 .03
Yes 2.85 1.1-7.5
DFS
TBI  10 Gy
No 1 .005
Yes 2.93 1.4-6.2
Liver involvement
No 1 .004
Yes 2.69 1.4-5.3
Lung involvement
No 1 <.001
Yes 4.4 2.0-9.6
HR indicates hazard ratio.
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were the skin (n ¼ 11), eyes (n ¼ 4), fascia (n ¼ 4), mouth
(n ¼ 2), liver (n ¼ 2), GI tract (n ¼ 1), and lungs (score of 1 or
more) (n ¼ 7).DISCUSSION
As has been reported in a number of previous studies,
long-term survivors of pediatric HSCT have signiﬁcantly
higher risk of late effects and adverse health status, including
physical, psychological, and cognitive problems, compared
with cancer survivors who did not undergo HSCT [22-25] or
the general population [22,26,27]. Most of these studies have
demonstrated that cGVHD had a signiﬁcant impact on many
aspects of health status resulting in a worse health-relatedTable 4
Causes of Nonrelapse Death for Patients with cGVHD
Cause Entire study cohort (n ¼ 105)
Invasive fungal infection 6
Bacterial pneumonia 2
Necrotizing soft tissue infection 1
BO 5
Idiopathic interstitial pneumonia 2
Intracranial hemorrhage 2
Second malignant neoplasm 2
Accident 1
Suicide 1
Total 22 (21%)QOL [28]. One large study of long-term health-related out-
comes in survivors of childhood cancer from the Bone
Marrow Transplant Survivor Study and Childhood Cancer
Survivor Study showed that allogeneic HSCT recipients with
active cGVHD were at greater risk for poor general health,
functional impairment, activity impairment, and pain
compared with the survivors treated with conventional
therapy [22].
One of the main objectives of the present study was to
investigate the prevalence of morbidity due to long-lasting
symptoms of cGVHD in pediatric HSCT survivors. We evalu-
ated the outcomes of cGVHD on the basis of the functional
status of the involved organs according to NIH score, ie,
cGVHD remission was deﬁned as the achievement of a score
of 0 or 1 (no clinically signiﬁcant functional impairment) in
all affected organs, because we were primarily concerned
with the debilitating sequelae that might affect QOL. In the
entire study cohort, the cumulative incidence of cGVHD
remission was 44.6% and the probability of continuing
cGVHD was 20.9% at 8 years after diagnosis of cGVHD. These
results were similar to those described in 2 large retrospec-
tive studies on children from the Center for International
Blood and Marrow Transplant Research [14] and the Italian
Association for Pediatric Hematology and Oncology [10]. The
results of the present study suggest that most surviving pa-
tients who developed mild and moderate cGVHD eventually
achieved cGVHD remission, whereas only approximately one
third of the surviving patients who developed severe cGVHD
achieved remission, even after 8 years from diagnosis of
cGVHD. For long-term survivors with continuing cGVHD, the
major impaired organs were the skin, followed by lungs,
eyes, and fascia, and their performance scores at the last
follow-up were poor. Most of these functional deﬁcits will
continue for the rest of the patients’ lives and may compro-
mise their QOL. Besides these sequelae of involved organs by
cGVHD, we should also consider the risk of a worsening of
health status caused by prolonged IST, such as diabetes
mellitus, osteoporosis, and recurrent infections. Compre-
hensive and continuous support, including medical care and
welfare, will be necessary.
As described for adult cGVHD patients [15,19,20], the re-
sults of the present study demonstrated that the NIH global
score could predict the risk of mortality even in childrenwith
cGVHD. Consistent with the lower cumulative incidence of
cGVHD remission, the cumulative incidence of NRM was
signiﬁcantly higher in patients with severe cGVHD. Most
causes of death were associated with cGVHD, including BO
and fatal infections during long-term IST. The risk of NRM
continued to increase even 10 years after the diagnosis of
cGVHD, as reported in a previous study [3]. Therefore, pa-
tients with severe cGVHD showed lower probability of DFS
compared with those with mild and moderate cGVHD.
Considering the higher mortality as well as poorer QOL, ef-
forts to lessen the risk of developing severe cGVHD are
necessary. The effectiveness of post-transplantation cyclo-
phosphamide [29] and antithymocyte globulinecontaining
pretransplantation conditioning regimen [30] has been re-
ported as prophylaxis for acute and cGVHD in various situ-
ations of HSCT, ranging from HLA-matched related BM
transplantation to haploidentical PB stem cell trans-
plantation. Therefore, decreased risk of developing severe
cGVHD is expected in future.
Several factors associated with increased risk of NRM
were previously identiﬁed among adult and children with
cGVHD, such as low performance score, thrombocytopenia,
Figure 2. Frequency of continuing cGVHD and other events. (A) All events that occurred in patients with mild cGVHD. The probability of continuing cGVHD at 8 years
after diagnosis of cGVHD was 3.8% (95% CI, .3 to 16.4). (B) All events in patients with moderate cGVHD. The probability of continuing cGVHD at 8 years was 11.4% (95%
CI, 2.9 to 26.3). (C) All events in patients with severe cGVHD. The probability of continuing cGVHD at 8 years was 36.1% (95% CI, 21.9 to 50.4).
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onset of cGVHD, and poor response to ﬁrst-line treatment
[13,14,17]. In the present study, in the multivariate analysis, 5
risk factors (severe cGVHD, 3 or more affected organs, lung
involvement, PB as the stem cell source, and positive CMV
antigenemia after HSCT) were identiﬁed. It is reasonable that
3 or more affected organs and lung involvement were asso-
ciated with higher NRM because these factors are closely
associated with the severity of cGVHD. PB stem cell trans-
plantationwas also identiﬁed as a risk factor for higher NRM,as reported from previous studies in children with cGVHD
from the Center for International Blood and Marrow Trans-
plant Research [14]. Over the past decade, the number of PB
stem cell transplantations from both related and unrelated
donors has increased and has been reported to be associated
with the higher incidence and severe manifestations of
cGVHD and with prolonged IST, compared with BM trans-
plantations, mainly in adult patients without signiﬁcant
differences in survival [7,8,16,31,32]. However, it is uncertain
whether the higher incidence of severe cGVHD after PB stem
J. Inagaki et al. / Biol Blood Marrow Transplant 21 (2015) 1973e1980 1979cell transplantation will reduce survival with longer follow-
up in children.
Positive CMV antigenemia after HSCT was identiﬁed as a
risk factor for higher NRM and lower incidence of relapse in
the present study. The inﬂuence of CMV reactivation after
HSCT on HSCT outcomes in patients with hematological
malignancy has been reported [33-35]. A previous study
demonstrated that developing CMV antigenemia after HSCT
is a strong and independent predictor of a reduced risk of
leukemic relapse and superior survival in adult patients with
acute myeloid leukemia [33], whereas another study showed
no survival beneﬁt because CMV reactivation was associated
with increased NRM [34]. There may be similar effects of
CMV reactivation on the antileukemic effect and on the
toxicity after HSCT, even in the cohort limited to the patients
who developed cGVHD.
The limitations of the present study include its retro-
spective design, use of a single-center experience, small
number of patients included, and heterogeneity of trans-
plantation factors, such as stem cell source, donor type, and
HLA disparity. In addition, the possibility of ambiguities in
the diagnosis of cGVHD cannot be eliminated because of the
diagnostic bias of the attending physicians, particularly for
patients diagnosed before 2005, and the relatively low
number of histologically conﬁrmed diagnoses. The evalua-
tion of treatment response and cGVHD outcomes also
depend on the subjectivity of the attending physicians
without the performance of objective measurements. On the
other hand, the strength of the present study is that the
observational period was long enough to indicate the late
morbidity and mortality among children with cGVHD. In
addition, we analyzed the detailed outcomes of cGVHD,
including the functional status of involved organs, length of
IST exposure, and performance score in each patient with
close follow-up, which may be the beneﬁt of a single-center
study.
A number of previous studies have shown that cGVHD
was associated with a lower incidence of relapse; however,
data on the survival beneﬁt of cGVHD are conﬂicting mainly
because of higher NRM in patients with extensive/severe
cGVHD for hematological malignancies. With longer follow-
up periods, the undesirable effects of persistent cGVHD will
be more evident, particularly in pediatric HSCT survivors. In
addition, effective salvage treatments for steroid-refractory
cGVHD remain to be established. Therefore, developing
better therapeutic strategies, including drug-mediated
methods and graft manipulation, is needed to lower the
incidence of severe cGVHD.ACKNOWLEDGMENTS
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